AC
IRD

Annandale Capital’s Opus Genetics IRD Stock Holding History

Annandale Capital’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41K Hold
10,000
– – 0.01% 127
2026
Q1 		$46K Hold
10,000
– – 0.01% 120
2025
Q4 		$20K Hold
10,000
– – ﹤0.01% 126
2025
Q3 		$16.5K Buy
+10,000
New +$12.4K ﹤0.01% 124

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Annandale Capital's IRD Position: Q2 2026 in Review

Annandale Capital held its Opus Genetics (IRD) position steady in Q2 2026 at 10,000 shares worth $41K. The position accounts for 0.01% of the portfolio, ranked #127.

Annandale Capital first reported a position in IRD in Q3 2025 and has held it in 4 quarters since. The position peaked at $46K in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Annandale Capital held 10,000 shares of Opus Genetics worth $41K as of Q2 2026.
  • Annandale Capital left its Opus Genetics share count unchanged in Q2 2026.
  • Opus Genetics made up 0.01% of Annandale Capital's portfolio in Q2 2026, its #127 holding.
  • Annandale Capital first reported a position in Opus Genetics in Q3 2025 and has held it in 4 quarters since.
  • Annandale Capital's Opus Genetics position peaked at $46K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Annandale Capital's 13F filing for Q2 2026, filed 13 Aug 2026.